Immunic, Inc.
IMUXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Valued at $98.5M, IMUX is a micro-cap name in its sector. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Market Cap
$98.5M
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
-2.97
EPS (TTM)
$-3.69
EPS (Fwd)
$-2.43
ROE
-138.2%
ROA
-66.8%
Cash
$155.1M
Total Debt
$567,000
Free CF
-$51.4M
52W Change
-7.4%
Annual Financials
Cash vs Debt
Where IMUX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMUX finished 43.99% below its 150-day moving average ($12.48) and 38.95% below its 200-day moving average ($11.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMUX overbought or oversold?
At the October 20, 2026 close, IMUX's RSI(14) was 31.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Immunic, Inc. holds $155.1M in cash against $567K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$51.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -138.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMUX.